Status:
COMPLETED
PMS of Trazenta on the Long-term Use as Add-on Therapy
Lead Sponsor:
Boehringer Ingelheim
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
Brief Summary
Study to investigate the safety and efficacy of long-term daily use of Trazenta® Tablets as add-on therapy in patients with type 2 diabetes mellitus.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients with type 2 diabetes mellitus who are treated with anti-diabetic drugs and have never been treated with Trazenta® Tablets (linagliptin) before enrollment will be included.
- Exclusion criteria:
- None
Exclusion
Key Trial Info
Start Date :
July 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 4 2018
Estimated Enrollment :
4057 Patients enrolled
Trial Details
Trial ID
NCT01904383
Start Date
July 1 2013
End Date
October 4 2018
Last Update
October 2 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Locations, Japan